Clinical Trials Logo

Brain Metastases, Adult clinical trials

View clinical trials related to Brain Metastases, Adult.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06401824 Not yet recruiting - NSCLC Stage IV Clinical Trials

Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

Start date: July 1, 2024
Phase: Phase 2
Study type: Interventional

This study will evaluate whether the combination of sacituzumab govitecan (SG) and bevacizumab will result in shrinkage of brain metastases from patients with non-squamous non-small cell lung cancer (NSCLC), with disease progression on chemotherapy and immunotherapy.

NCT ID: NCT05620914 Not yet recruiting - Clinical trials for Brain Metastases, Adult

A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases

PARAMETer
Start date: April 2024
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to determine if the study drug, patritumab deruxtecan (HER3-DXd), can be measured in brain tumor tissue after recieving one dose of patritumab deruxtecan before surgery.

NCT ID: NCT04626206 Not yet recruiting - Clinical trials for Brain Metastases, Adult

Multi -paramEtric Imaging to Assess Treatment REsponse After Stereotactic Radiosurgery of Brain Metastases

METRE
Start date: December 2020
Phase:
Study type: Observational

After stereotactic radiosurgery (SRS) of brain metastases, patients undergo a standard brain magnetic resonance imaging (MRI) to assess treatment response 12 weeks after completion of treatment. The interpretation of this standard MRI can sometimes be challenging as it can be difficult to differentiate tumour getting bigger/returning (progression/recurrence) from expected radiotherapy treatment-related changes known as radionecrosis. This study is a pilot brain imaging study that is investigating if readily available forms of imaging such as contrast-clearance analysis MRI (also known as TRAMs) and/or 18 Fluoromethyl-choline positron emission tomography/computerised tomography (18F-choline PET/CT) are equivalent to multi-parametric MRI in their ability to differentiate tumour from radionecrosis. Multi-parametric MRI has the most evidence for its ability to discriminate tumour from radionecrosis but is resource intensive and not routinely available in most centres.